NASDAQ · PODD
Healthcare · Medical - Devices
$135.28
Up+$0.81 (+0.60%)
Updated Oct 11, 2026, 3:00 AM
SID Score
4.9/10
Composite research score
Smart Money
58/100
Neutral
Price performance · PODD
1M range · 0 trading sessions · Daily adjusted prices
PODD does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
The latest Smart Investors Daily articles mentioning PODD.
Company
Market Activity
Research & News
PODD research
Company profile and research snapshot.
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 7, 2026 | Barclays | Equal-Weight | — |
| Aug 6, 2026 | Leerink Partners | Market Perform | — |
| Aug 6, 2026 | Benchmark | Buy | — |
| Aug 6, 2026 | Bernstein | Outperform | — |
| Aug 6, 2026 | RBC Capital | Outperform | — |
No generated briefing is available yet.
Benzinga · Oct 8, 2026
Insulet (NASDAQ:PODD) released second-quarter financial results and hosted an earnings call on Wednesday. Read the complete transcript below. This content is powered by Benzinga APIs. For comprehensive financial data
Yahoo · Oct 7, 2026
Intel downgraded, Marvell upgraded: Wall Street's top analyst calls
Benzinga · Oct 7, 2026
Barclays analyst Christopher Pasquale initiates coverage on Insulet (NASDAQ:PODD) with a Equal-Weight rating and announces Price Target of $150.
Yahoo · Oct 1, 2026
A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who prioritize stability may miss out on higher-reward opportunities elsewhere.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning PODD.
